Aprea Therapeutics, Inc. (APRE)

In the past six months, Aprea Therapeutics' stock price has been positively impacted by positive clinical trial results for APR-1051, a successful oversubscribed $30 million private placement, and favorable analyst coverage. A recommended Phase 2 dose was identified for ATRN-119. Despite these positive events, the stock price experienced a decline of 50.40% between May 6, 2025, and May 5, 2026. However, APRE has outperformed the overall market in the last three months and two-week periods, returning +42.0% and +10.8%, respectively.

Aprea Therapeutics, Inc. does not experience traditional demand seasonality for its products and services. The demand for its investigational therapies is driven by ongoing clinical trials, regulatory milestones, and the progression of its drug pipeline. The company's revenue generation primarily comes from partnerships, licensing agreements, and potential future product sales upon regulatory approval.

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology, discovering and developing targeted therapies for biomarker-defined cancers. They operate in the biotechnology and pharmaceutical sector, developing novel cancer therapeutics that target DNA damage response pathways, exploiting cancer cell mutations to destroy tumor cells while minimizing harm to healthy tissue. Their lead product candidates include APR-1051, a small molecule WEE1 inhibitor in Phase 1 clinical trials; ATRN-119 (Mosipasertib), a novel macrocyclic ATR inhibitor in Phase 1/2a clinical trials; and APR-1602, an early-stage DYRK1 inhibitor program ready to enter IND-enabling studies. Previously, APR-246 (eprenetapopt) was a lead product candidate in clinical development, and APR-548 was in preclinical development.

Aprea Therapeutics, Inc. is headquartered in Doylestown, Pennsylvania, United States. The company also has a wholly-owned subsidiary, Aprea Therapeutics AB, incorporated in Sweden in 2003. Research facilities were previously noted in Stockholm, Sweden.

Aprea Therapeutics maintains a brand reputation focused on its pioneering approach to precision oncology and its commitment to developing cutting-edge cancer therapies. Positive clinical data for APR-1051, the successful $30 million private placement, and favorable analyst coverage have positively affected the company's reputation. Challenges impacting its reputation include a declared "going concern" risk and a history of FDA safety holds.

The ownership structure of Aprea Therapeutics stock includes institutional investors owning approximately 8.20% to 9.21%, insiders owning 6.30%, and public companies and individual investors (retail investors) owning 84.49%. Major institutional shareholders include AIGH Capital Management LLC, Murchinson Ltd., Sphera Funds Management Ltd., Nantahala Capital Management, LLC, DRW Securities, LLC, Morgan Stanley, Vanguard Group Inc, Citadel Advisors Llc, Jane Street Group, Llc, and Geode Capital Management, Llc. Oren Gilad is noted as owning the most shares of Aprea Therapeutics Inc..